Evidence map›Paper›PMID 40528211›Full record

ArticleJournal of translational medicine2025

Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.

Zhan Wang, Zhaokai Zhou, Shuai Yang, Zhengrui Li, Run Shi, Ruizhi Wang, Kui Liu, Xiaojuan Tang, Qi Li

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhan Wang *Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China.
Zhaokai Zhou *Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Shuai Yang *Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China.
Zhengrui Li *Department of Oral and Cranio-Maxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Run ShiDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ruizhi WangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China.
Kui LiuDepartment of Pediatric Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000, China.
Xiaojuan TangDepartment of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Qi LiDepartment of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China. siloam1994@163.com.

Funding

Joint Co-construction Project of Henan Medical Science and Technology Research Program LHGJ20240277the Postdoctoral Fellowship Program of CPSF GZC20241552Youth Fund Project of Natural Science Foundation of Henan Province 252300420529
6 · The paper itself

Abstract

backgroundThe heterogeneity of bladder cancer (BLCA) is affected by its inherent transcriptional properties and tumor microenvironment (TME). Stromal transcriptional components in the TME significantly influence the transcriptional classification of BLCA, and the intrinsic biological transcriptional characteristics of cancer cells may be obscured by the dominant, lineage-dependent transcriptional components of stromal origin. This study aimed to explore the degree and mechanisms by which cancer-intrinsic gene expression profiles contribute to the classification and prognosis of BLCA patients. MATERIALS AND

methodsIn this study, BLCA single-cell transcriptome data from GSE135337 were used to identify pure tumor cells in BLCA and explore the different intrinsic heterogeneous cell subgroups of BLCA through pathway-based cancer transcriptome classification. Additionally, BLCA intrinsic subtypes were uncovered in the TCGA BLCA dataset based on the characteristic genes of the subgroups. Lastly, various machine learning algorithms were applied to identify novel potential targets of BLCA, following which their pro-tumorigenic effects were experimentally verified.

resultsFour BLCA intrinsic subtypes with different molecular, functional and phenotypic characteristics were successfully identified. Specifically, MA and DP subtypes demonstrated malignant phenotypes, accompanied by unfavorable clinical prognoses, limited involvement in cell death pathways, marked cell proliferation, and diminished immune activation. Notably, MA subtype exhibited the most favorable response to immunotherapy, potentially attributable to its distinctive tumor immune microenvironment. DSM subtype represented an immune-rich subtype with the optimal prognosis, characterized by abundant immune cells, high levels of co-stimulatory, co-inhibitory, major histocompatibility complex molecules, and a potential for immunotherapy response. On the other hand, HM subtype was associated with a high level of autophagy and necrosis and an "immune-hot" TIME. Furthermore, BLCA intrinsic subtypes effectively classified independent sets of BLCAs, with limited overlap with existing transcriptional classifications and showcasing unprecedented predictive and prognostic value. Finally, the DP subtype, associated with the worst prognosis, was further analyzed, leading to the identification of three potential target genes (DAD1, CYP1B1, and REXO2) significantly associated with metabolic disorders, as well as BLCA stage and grade.

conclusionThis study identified a promising platform for understanding intrinsic tumor heterogeneity, which could offer new insights into the intricate molecular mechanisms of BLCA. Targeted therapy against BEXO2 may improve the prognosis of BLCA patients by regulating mitochondria-related metabolic disorders.

Indexed as

Genetic HeterogeneitySignal TransductionTranscriptomeUrinary Bladder NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBladder cancerImmune microenvironmentIntrinsic heterogeneityMetabolic disorderMolecular subtypesSingle-cell RNA-seq

Identifiers

PMID40528211
PMCPMC12175387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.